Search
DOTMP HO-166
go.drugbank.com/drugs/DB05380ExperimentalIt is an experimental therapy that is being developed by NeoRx Corporation. … SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in
Topiroxostat
go.drugbank.com/drugs/DB01685InvestigationalWhile [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens … Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout.
Aminophylline
go.drugbank.com/drugs/DB01223ApprovedInvestigationalAminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. … Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator.
Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexNUC B1000
go.drugbank.com/drugs/DB05242ExperimentalNUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid … the RNAi response against a targeted disease causing gene.
PGX-100
go.drugbank.com/drugs/DB06114InvestigationalIt is a nearly nonanticoagulant heparin derivative that retains its anti-inflammatory activity. … PGX-100 is an intravenous dosage form of modified heparin.
Tulrampator
go.drugbank.com/drugs/DB16344InvestigationalTulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive
FB-101
go.drugbank.com/drugs/DB17956InvestigationalFB-101 is a c-Abl inhibitor. … Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).[L47102]